- Report
- March 2025
- 250 Pages
Global
From €4288EUR$4,490USD£3,586GBP
- Report
- May 2024
- 259 Pages
Global
From €3343EUR$3,500USD£2,795GBP
€4775EUR$5,000USD£3,993GBP
- Report
- March 2025
- 89 Pages
Global
From €5348EUR$5,600USD£4,472GBP
- Report
- March 2025
- 159 Pages
Global
From €5205EUR$5,450USD£4,353GBP
- Report
- February 2025
- 200 Pages
Global
From €4288EUR$4,490USD£3,586GBP
- Report
- March 2025
- 89 Pages
Global
From €5348EUR$5,600USD£4,472GBP
- Report
- October 2023
- 414 Pages
Global
From €4727EUR$4,950USD£3,953GBP
- Report
- May 2023
- 367 Pages
Global
From €3343EUR$3,500USD£2,795GBP
€4775EUR$5,000USD£3,993GBP
- Report
- October 2023
- 176 Pages
Global
From €4298EUR$4,500USD£3,594GBP
- Report
- August 2022
- 180 Pages
Global
From €3524EUR$3,690USD£2,947GBP
The Animal Testing Alternative market is a subset of the biotechnology industry that focuses on the development of non-animal testing methods for the safety assessment of products. These alternatives are designed to replace, reduce, or refine the use of animals in research and testing. The market is driven by the need to reduce animal suffering, as well as the increasing demand for more accurate and reliable testing methods. Companies in this market are developing a range of technologies, such as in vitro cell-based assays, computer-based models, and tissue engineering.
Some companies in the Animal Testing Alternative market include Cyprotex, In Vitro ADMET Laboratories, InVitro International, MatTek Corporation, and Toxikon Corporation. Show Less Read more